Mesa Laboratories, Inc. (MLAB) Income Statement Analysis

See more : W.I.S.E. – SSE 50 China Tracker (3024.HK) Income Statement Analysis – Financial Results

Complete financial analysis of Mesa Laboratories, Inc. (MLAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mesa Laboratories, Inc., a leading company in the Hardware, Equipment & Parts industry within the Technology sector.

You may be interested

Mesa Laboratories, Inc. (MLAB)

Industry: Hardware, Equipment & Parts

Sector: Technology

Website: https://www.mesalabs.com

About Mesa Laboratories, Inc.

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988
Revenue	216.19M	219.08M	184.34M	133.94M	117.69M	103.14M	96.18M	93.67M	84.66M	71.33M	52.72M	46.44M	39.62M	32.83M	21.93M	21.54M	19.56M	17.24M	11.58M	10.04M	9.13M	9.08M	9.04M	9.10M	8.66M	8.10M	7.90M	7.80M	8.10M	6.60M	6.20M	4.40M	3.80M	3.50M	2.80M	1.10M	1.00M
Cost of Revenue	82.94M	85.39M	75.25M	46.92M	52.75M	42.22M	41.56M	40.43M	33.25M	27.94M	21.04M	17.57M	16.11M	13.26M	8.74M	7.72M	6.70M	6.35M	4.15M	3.72M	3.43M	3.40M	3.65M	3.07M	2.80M	2.40M	2.50M	2.70M	2.80M	2.20M	2.10M	1.40M	1.20M	1.20M	1.20M	400.00K	400.00K
Gross Profit	133.25M	133.69M	109.09M	87.01M	64.93M	60.92M	54.62M	53.24M	51.41M	43.39M	31.69M	28.86M	23.51M	19.57M	13.19M	13.82M	12.86M	10.90M	7.44M	6.32M	5.70M	5.68M	5.39M	6.03M	5.85M	5.70M	5.40M	5.10M	5.30M	4.40M	4.10M	3.00M	2.60M	2.30M	1.60M	700.00K	600.00K
Gross Profit Ratio	61.64%	61.02%	59.18%	64.97%	55.17%	59.06%	56.79%	56.84%	60.73%	60.83%	60.10%	62.16%	59.35%	59.61%	60.17%	64.16%	65.74%	63.19%	64.21%	62.94%	62.44%	62.59%	59.61%	66.30%	67.62%	70.37%	68.35%	65.38%	65.43%	66.67%	66.13%	68.18%	68.42%	65.71%	57.14%	63.64%	60.00%
Research & Development	19.30M	20.49M	15.77M	10.39M	6.36M	3.51M	3.54M	4.16M	3.97M	3.29M	2.32M	2.01M	1.36M	1.44M	669.00K	636.00K	532.00K	392.00K	358.00K	358.00K	332.00K	259.97K	289.94K	308.17K	281.65K	200.00K	300.00K	300.00K	300.00K	400.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	72.87M	72.44M	60.31M	45.70M	37.83M	31.30M	26.26M	22.81M	23.62M	17.06M	11.46M	9.12M	5.42M	4.58M	2.54M	2.52M	5.27M	4.84M	2.97M	2.49M	2.12M	2.24M	2.16M	2.40M	2.39M	2.20M	2.10M	2.10M	2.30M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	38.63M	37.44M	28.31M	18.48M	12.91M	8.26M	8.82M	9.96M	7.50M	7.18M	6.12M	4.63M	3.91M	3.69M	2.62M	3.05M	2.85B	2.77B	1.88B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	111.49M	109.88M	88.62M	64.18M	50.74M	39.56M	35.08M	32.77M	31.12M	24.23M	17.58M	13.75M	9.33M	8.26M	5.16M	5.57M	5.27M	4.84M	2.97M	2.49M	2.12M	2.24M	2.16M	2.40M	2.39M	2.20M	2.10M	2.10M	2.30M	1.80M	2.30M	1.60M	1.30M	1.20M	1.00M	600.00K	600.00K
Other Expenses	274.53M	-3.71M	-1.13M	91.00K	50.00K	-1.16M	-1.88M	-2.02M	-768.00K	-517.00K	1.32M	-126.00K	350.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	332.59K	200.00K	200.00K	200.00K	300.00K	300.00K	200.00K	100.00K	100.00K	200.00K	100.00K	0.00	0.00
Operating Expenses	406.55M	130.37M	104.39M	74.66M	57.14M	43.06M	38.62M	36.93M	35.09M	27.53M	19.90M	15.76M	10.68M	9.70M	5.83M	6.21M	5.80M	5.24M	3.33M	2.85M	2.45M	2.50M	2.45M	2.71M	3.01M	2.60M	2.60M	2.60M	2.90M	2.50M	2.50M	1.70M	1.40M	1.40M	1.10M	600.00K	600.00K
Cost & Expenses	488.26M	215.76M	179.63M	121.58M	109.90M	85.28M	80.18M	77.35M	68.34M	55.47M	40.94M	33.33M	26.79M	22.96M	14.56M	13.93M	12.50M	11.58M	7.47M	6.57M	5.88M	5.90M	6.10M	5.77M	5.81M	5.00M	5.10M	5.30M	5.70M	4.70M	4.60M	3.10M	2.60M	2.60M	2.30M	1.00M	1.00M
Interest Income	0.00	4.77M	3.89M	107.00K	960.00K	1.72M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	86.00K	195.00M	130.00M	193.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	5.70M	3.71M	3.89M	8.02M	5.50M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	31.57M	33.13M	25.07M	17.47M	12.87M	9.47M	9.47M	8.74M	7.17M	5.66M	3.84M	3.43M	2.22M	1.84M	786.00K	788.00K	742.00K	669.00K	93.00K	90.00K	97.00K	115.35K	115.09K	521.69K	332.59K	200.00K	200.00K	200.00K	300.00K	300.00K	200.00K	100.00K	100.00K	200.00K	100.00K	0.00	0.00
EBITDA	-238.38M	36.45M	29.77M	12.36M	8.09M	18.09M	9.77M	25.05M	23.50M	21.52M	15.63M	16.54M	14.55M	11.71M	8.15M	8.40M	7.80M	6.33M	4.20M	3.57M	3.35M	3.30M	3.06M	3.85M	3.18M	3.30M	3.20M	2.70M	2.70M	2.20M	1.80M	1.40M	1.30M	1.10M	600.00K	100.00K	0.00
EBITDA Ratio	-110.26%	1.52%	2.55%	9.23%	6.87%	34.28%	31.01%	17.42%	19.28%	22.24%	22.35%	28.22%	39.22%	36.01%	33.76%	38.99%	39.90%	36.70%	36.29%	35.50%	36.66%	36.36%	33.80%	43.13%	36.72%	37.04%	35.44%	33.33%	32.10%	33.33%	29.03%	29.55%	31.58%	31.43%	21.43%	9.09%	0.00%
Operating Income	-272.08M	-30.50M	-20.37M	-5.30M	-4.90M	9.78M	2.18M	16.31M	16.32M	15.86M	11.79M	13.10M	12.48M	9.86M	7.37M	7.61M	7.06M	5.66M	4.11M	3.48M	3.25M	3.19M	2.94M	2.81M	2.85M	3.10M	2.80M	2.50M	2.40M	1.90M	1.60M	1.30M	1.20M	900.00K	500.00K	100.00K	0.00
Operating Income Ratio	-125.85%	-13.92%	-11.05%	-3.96%	-4.16%	9.48%	2.27%	17.42%	19.28%	22.24%	22.35%	28.22%	31.49%	30.05%	33.60%	35.33%	36.10%	32.82%	35.48%	34.61%	35.60%	35.09%	32.53%	30.84%	32.87%	38.27%	35.44%	32.05%	29.63%	28.79%	25.81%	29.55%	31.58%	25.71%	17.86%	9.09%	0.00%
Total Other Income/Expenses	-3.57M	-3.71M	-1.13M	-10.06M	-4.06M	-1.16M	-1.88M	-2.02M	-768.00K	-517.00K	1.32M	-126.00K	-146.00K	-113.00K	36.00K	86.00K	195.00K	130.00K	193.00K	98.00K	50.00K	55.16K	78.51K	70.96K	243.83K	100.00K	400.00K	100.00K	0.00	-100.00K	-100.00K	0.00	100.00K	100.00K	0.00	100.00K	0.00
Income Before Tax	-275.65M	-389.00K	3.57M	2.30M	3.43M	8.62M	301.00K	14.30M	15.56M	15.35M	13.10M	12.98M	12.33M	9.75M	7.40M	7.69M	7.26M	5.79M	4.30M	3.57M	3.30M	3.24M	3.02M	2.88M	3.09M	3.20M	3.20M	2.60M	2.40M	1.80M	1.50M	1.30M	1.30M	1.00M	0.00	200.00K	0.00
Income Before Tax Ratio	-127.50%	-0.18%	1.94%	1.72%	2.92%	8.36%	0.31%	15.26%	18.37%	21.52%	24.85%	27.95%	31.13%	29.71%	33.76%	35.73%	37.10%	33.57%	37.15%	35.58%	36.15%	35.69%	33.40%	31.62%	35.69%	39.51%	40.51%	33.33%	29.63%	27.27%	24.19%	29.55%	34.21%	28.57%	0.00%	18.18%	0.00%
Income Tax Expense	-21.40M	-1.32M	1.70M	-971.00K	2.08M	1.14M	3.26M	3.11M	4.39M	5.76M	4.10M	4.53M	4.41M	3.57M	2.64M	2.90M	2.65M	1.83M	1.50M	1.26M	1.17M	1.11M	989.66K	1.05M	982.46K	1.10M	1.10M	900.00K	800.00K	600.00K	500.00K	400.00K	400.00K	100.00K	100.00K	100.00K	0.00
Net Income	-254.25M	930.00K	1.87M	3.27M	1.35M	7.48M	-2.96M	11.18M	11.17M	9.58M	9.00M	8.45M	7.92M	6.18M	4.77M	4.79M	4.61M	3.96M	2.81M	2.31M	2.13M	2.13M	2.03M	1.83M	2.11M	2.10M	2.10M	1.70M	1.60M	1.20M	1.00M	900.00K	900.00K	900.00K	400.00K	100.00K	0.00
Net Income Ratio	-117.60%	0.42%	1.01%	2.44%	1.15%	7.26%	-3.08%	11.94%	13.19%	13.43%	17.07%	18.20%	19.99%	18.84%	21.75%	22.24%	23.57%	22.96%	24.22%	23.03%	23.34%	23.42%	22.46%	20.13%	24.34%	25.93%	26.58%	21.79%	19.75%	18.18%	16.13%	20.45%	23.68%	25.71%	14.29%	9.09%	0.00%
EPS	-47.20	0.17	0.36	0.66	0.32	1.95	-0.79	3.04	3.10	2.72	2.61	2.52	2.41	1.91	1.49	1.51	1.46	1.25	0.94	0.76	0.70	0.66	0.60	0.59	0.55	0.51	0.48	0.39	0.29	0.29	0.23	0.21	0.21	0.20	0.10	0.04	0.01
EPS Diluted	-47.20	0.17	0.35	0.64	0.31	1.86	-0.79	2.91	2.97	2.63	2.49	2.35	2.29	1.86	1.45	1.48	1.41	1.22	0.92	0.74	0.68	0.64	0.59	0.59	0.55	0.50	0.47	0.39	0.29	0.29	0.23	0.21	0.21	0.20	0.10	0.04	0.01
Weighted Avg Shares Out	5.39M	5.32M	5.21M	4.98M	4.20M	3.84M	3.75M	3.68M	3.61M	3.52M	3.45M	3.36M	3.29M	3.23M	3.19M	3.18M	3.17M	3.16M	2.99M	3.06M	3.05M	3.23M	3.41M	3.69M	3.82M	4.14M	4.30M	4.47M	4.33M	4.14M	4.35M	4.29M	4.29M	4.50M	4.00M	2.50M	3.48M
Weighted Avg Shares Out (Dil)	5.39M	5.36M	5.34M	5.12M	4.37M	4.03M	3.77M	3.84M	3.76M	3.65M	3.61M	3.59M	3.46M	3.33M	3.29M	3.24M	3.28M	3.23M	3.05M	3.14M	3.14M	3.30M	3.45M	3.72M	3.84M	4.17M	4.40M	4.47M	4.33M	4.14M	4.35M	4.29M	4.29M	4.50M	4.00M	2.50M	3.48M

Mesa Labs (MLAB) Lags Q2 Earnings and Revenue Estimates

November 7, 2024zacks.com

Mesa Labs (MLAB) came out with quarterly earnings of $2.45 per share, missing the Zacks Consensus Estimate of $2.48 per share. This compares to earnings of $1.91 per share a year ago.

Mesa Labs Announces Second Quarter Results

November 7, 2024globenewswire.com

LAKEWOOD, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its second fiscal quarter (“2Q25”) ended September...

MESA LABS DECLARES QUARTERLY DIVIDEND

October 2, 2024globenewswire.com

LAKEWOOD, Colo., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The...

Surging Earnings Estimates Signal Upside for Mesa Labs (MLAB) Stock

August 26, 2024zacks.com

Mesa Labs (MLAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Mesa Labs (MLAB) Moves to Strong Buy: Rationale Behind the Upgrade

August 26, 2024zacks.com

Mesa Labs (MLAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for August 26th

August 26, 2024zacks.com

QFIN, GHM, CRNC, SUPV and MLAB have been added to the Zacks Rank #1 (Strong Buy) List on August 26, 2024.

Mesa Labs Announces First Quarter Results

August 5, 2024globenewswire.com

LAKEWOOD, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its first fiscal quarter (“1Q25”) ended June...

MESA LABS DECLARES QUARTERLY DIVIDEND

July 8, 2024globenewswire.com

Lakewood, Colo, July 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The...

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results

June 5, 2024globenewswire.com

LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q24”) and fiscal...

Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fiscal Year 2024 Results

May 31, 2024globenewswire.com

LAKEWOOD, Colo., May 31, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (“Mesa”) (NASDAQ:MLAB) will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 today as previously communicated. The earnings announcement has...

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

Mesa Laboratories, Inc. (MLAB) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories